Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review

Pai, Madhukar; Riley, Lee W.; Colford, John M.

doi:10.1016/s1473-3099(04)01206-x

Cited by 875 publications

(738 citation statements)

References 84 publications

Supporting

Mentioning

659

Contrasting

Unclassified

Order By: Relevance

“…Such testing has previously been used in immunosuppressed patients as an aid in interpreting negative TST results; however, previous studies have failed to demonstrate the usefulness of anergy testing in HIV-infected persons (24). The wholeblood assay QuantiFERON-TB Gold (Cellestis Limited, Abbotsford, Victoria, Australia) might offer a more specific alternative to the TST, since it assesses patient immune responses to antigens highly specific for TB and not found in BCG, but further research is needed to determine its sensitivity and specificity for LTBI in immunosuppressed patients (25,26).…”

Section: Interim Recommendations For the Prevention And Management Ofmentioning

confidence: 99%

Tuberculosis associated with therapy against tumor necrosis factor α

Winthrop¹,

Siegel²,

Jereb³

et al. 2005

Arthritis & Rheumatism

103

View full text Add to dashboard Cite

Section: Interim Recommendations For the Prevention And Management Ofmentioning

confidence: 99%

Tuberculosis associated with therapy against tumor necrosis factor α

Winthrop¹,

Siegel²,

Jereb³

et al. 2005

Arthritis & Rheumatism

103

View full text Add to dashboard Cite

“…The advent of interferon-c-based assays allowed to gauge cytokine secretion in response to antigenic in vitro stimulation, indicative of pre-exposure to MTB. Incubation times range in different IFN-c assay systems from 24 hours up to six days [1]. The new generation of IFNc-based assays uses antigens specific for MTB, e.g.…”

Section: Introductionmentioning

confidence: 99%

MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis‐specific CD4⁺ T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis

Höhn¹,

Kortsik²,

Zehbe³

et al. 2007

Scand J Immunol

View full text Add to dashboard Cite

Novel diagnostic tools are needed to diagnose latent infection and to provide biologically meaningful surrogate markers to define cellular immune responses against Mycobacterium tuberculosis (MTB). Interferon gamma‐based assays have recently been developed in addition to the more than 100‐year‐old tuberculin skin test (TST) for the immune diagnosis of MTB in blood. The advent of soluble MHC/peptide tetramer molecules allows to objectively enumerate antigen‐specific T cells. We identified novel MHC class II‐restricted MTB epitopes and used HLA‐DR4 tetrameric complexes to visualize ex vivo CD4+ T cells directed against the antigens Ag85B and the 19‐kDa lipoprotein, shared between MTB and other Mycobacterium species, and CD4+ T cells which recognize the MTB‐associated ESAT‐6 antigen. MTB‐reactive CD4+ T cells reside predominantly in the CD45RA+ CD28+ and CD45− CD28+ T‐cell subset and recognize naturally processed and presented MTB epitopes. HLA‐DR4‐restricted, Ag85B or ESAT‐6‐specific CD4+ T cells show similar dynamics over time in peripheral blood mononuclear cells (PBMC) when compared with CD8+ T cells directed against the corresponding HLA‐A2‐presented MTB epitopes in patients with pulmonary MTB infection and subsequent successful therapy. This was not found to be true for T‐cell responses directed against the 19‐kDa lipoprotein. The dissection of the cellular immune response in M. tuberculosis infection will enable novel strategies for monitoring MTB vaccine candidates and to gauge CD4+ T cells directed against MTB.

show abstract

“…27 In addition to the two commercial kits described, other assays have been developed in research labs, but they are not yet commercially available. 28 The specificity of these tests is similar (98% to 99%), whereas sensitivity is higher for the T-SPOT.TB when compared to the QFT (90%). This difference is primarily pronounced in immunosuppressed patients and children, whose frequency of indeterminate results has been high.…”

Section: New Tools For the Diagnosis Of Ltbimentioning

confidence: 89%

Investigação de infecção tuberculosa latente em pacientes com psoríase candidatos ao uso de drogas imunobiológicas

Lima

Duarte

et al. 2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

The use of tumor necrosis factor inhibitors for the treatment of patients with psoriasis has been related to a higher incidence of tuberculosis, specially the disseminated and extrapulmonary forms. Despite their efficacy, these drugs increase the risk of reactivating latent tuberculosis infection, thus requiring diagnosis of the condition before their administration. Investigation of latent tuberculosis infection with tuberculin skin test is ineffective due to its low specificity and the dubious results that it generates in patients with psoriasis. Assays based on the detection of synthesis of gamma interferon in vitro by peripheral monoclonal cells, stimulated by specific antigens (ESAT-6 and CFP-10), seem to offer better accuracy when compared to the Mantoux test in identifying latent tuberculosis infection. This diagnosis tool has demonstrated higher specificity, since it has no correlation with indirect forms of exposure to M. tuberculosis such as BCG vaccination or with infections by other mycobacteria. Keywords: Psoriasis; Tuberculosis; Tumor necrosis factor-alpha Resumo: O uso dos ini bi do res do fator de necro se tumo ral no tra ta men to de pacien tes com pso ría se vem sendo rela cio na do a uma maior inci dên cia de tuber cu lo se, par ti cu lar men te, nas suas for mas extrapul mo nar e dis se mi na da. Apesar de sua indis cu tí vel efi cá cia, essas dro gas ele vam o risco da rea ti va ção de infec ção tuber cu lo sa laten te (ITBL), tor nan do obri ga tó rio o diag nós ti co da refe ri da con di ção antes da sua admi nis tra ção. A inves ti ga ção da infec ção tuber cu lo sa laten te pelo teste cutâ neo da tuber cu li na é falha, dada sua baixa espe ci fi ci da de, além de apre sen tar resul ta dos duvi do sos em pacien tes com psoría se. Ensaios basea dos na detec ção da pro du ção de inter fe ron-gama in vitro por célu las mono clo nais peri fé ri cas, esti mu la das por antí ge nos espe cí fi cos (Esat-6 e CFP-10), pare cem ofe re cer maior acu rá cia quan do com pa ra dos ao teste de Mantoux na iden ti fi ca ção de infec ção tuber cu lo sa laten te. Essa fer ramen ta diag nós ti ca tem ofe re ci do maior espe ci fi ci da de, já que não apre sen ta cor re la ção com medi das indi re tas de expo si ção ao M. tuber cu lo sis, como a vaci na ção por BCG, e com infec ções por outras micobac té rias. Palavras-chave: Fator de necro se tumo ral alfa; Tuberculose; Psoríase

show abstract

Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review

Cited by 875 publications

References 84 publications

Tuberculosis associated with therapy against tumor necrosis factor α

Tuberculosis associated with therapy against tumor necrosis factor α

MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis‐specific CD4⁺ T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis

Investigação de infecção tuberculosa latente em pacientes com psoríase candidatos ao uso de drogas imunobiológicas

Contact Info

Product

Resources

About

Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review

Cited by 875 publications

References 84 publications

Tuberculosis associated with therapy against tumor necrosis factor α

Tuberculosis associated with therapy against tumor necrosis factor α

MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis‐specific CD4+ T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis

Investigação de infecção tuberculosa latente em pacientes com psoríase candidatos ao uso de drogas imunobiológicas

Contact Info

Product

Resources

About

MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis‐specific CD4⁺ T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis